Pluri Inc. (PLUR) Stock

Pluri Inc., a pioneering biotechnology firm based in Haifa, Israel, specializes in advancing placenta-based cell therapy products aimed at treating a range of inflammatory, muscle injury, and hematologic conditions. At the forefront of its development efforts are PLX (placental expanded) cell therapy products. Among these, PLX-PAD is currently undergoing Phase III clinical trials to facilitate muscle recovery post-surgery for hip fractures. Additionally, in collaboration with Tel Aviv Sourasky Medical Center, PLX-PAD is in Phase I/II trials for treating steroid-refractory graft versus host disease, having also completed Phase II trials for addressing acute respiratory distress syndrome linked to COVID-19, and Phase I trials for managing incomplete recovery post-bone marrow transplantation.

Further expanding its therapeutic portfolio, Pluri Inc. is advancing PLX-R18, a product designed to address incomplete hematopoietic recovery following hematopoietic cell transplantation. Additionally, through collaborative efforts with the National Institutes of Health and the U.S. Department of Defense, Pluri Inc. is developing a solution targeting acute radiation syndrome. This underscores the company's commitment to leveraging placental-derived therapies to meet critical medical needs across various challenging conditions.

Originally known as Pluristem Therapeutics Inc., the company rebranded to Pluri Inc. in July 2022. Since its inception in 2001, Pluri Inc. has maintained a steadfast dedication to pioneering innovative cell therapies, positioning itself at the forefront of biotechnological advancements aimed at enhancing patient outcomes globally.